Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Canaccord's Quarterly NASH Report

<< Previous

Bullboard Posts

Next >>

Post by SPCEO1on Jan 22, 2021 10:09am

283 Views

Post# 32358553

Canaccord's Quarterly NASH Report

It came out this morning and I have not yet had time to sift through its 211 pages (That is correct - it is 211 pages)

But on the first page, he has a table that shows THTX will start a phase IIb/III trial in Q3.

Maybe he is betting the EMA will win and force a phase IIb before the III can get started. Or maybe he just did not have time to update such a huge effort for the latest news.

I will dig deeper into the report later and see if he explains his thinking.

There is still no standalone report on TH from him follwoing all the recent news. And still no new report from Mackie or RBC.

<< Previous

Bullboard Posts

Next >>

Propel steps onto world stage with QuidMarket acquisition